VALLOUREC starts exclusive negotiations with the Ascometal

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
VALLOUREC starts exclusive negotiations with the Ascometal Group for the sale of a majority holding in the Saint-Saulve steel mill

BOULOGNE BILLANCOURT, France, July 21, 2016 (GLOBE NEWSWIRE) -- Vallourec, global leader in premium tubular solutions, has started exclusive negotiations with Ascometal,  Europe's largest producer of special steels, with a view to the sale of its majority holding in the  Saint-Saulve steel mill (Hauts-de-France region). Based on a reinforced industrial and business plan, the Ascometal offer should retain the site's 320 highly skilled employees.

Negotiations should be concluded with a final agreement being signed by the end of 2016.

At this stage in proceedings, the two partners envisage creating a joint venture with Vallourec holding a 40% stake and Ascometal having a 60% holding, thus giving the latter exclusive control of operations. Furthermore, the Hauts-de-France region has confirmed its support for the transaction according to conditions which are still to be determined.

From an industrial viewpoint, the two shareholders will be supplied by the Saint-Saulve modern and high technology steel mill, Vallourec for its requirements in terms of special steels and Ascometal to supply its finishing units located in Dunkirk and Fos-sur-Mer, in the North and South of France.

The global industrial projects would include a significant investment program in order to both diversify production at the Saint-Saulve steel mill and meet Ascometal's new requirements. It means:

  • In Saint-Saulve, the upgrade of the existing equipment in order to produce steel bars with varying diameters which would pave the way to accessing new markets, in particular in the automotive industry.
  • In Dunkirk, new rolling capacity that would enable this plant to gain a foothold in new automotive markets.
  • In Fos-sur-Mer, new equipment that would enable the rod mill to use the semi-finished products made with the Saint-Saulve continuous casting, in addition to the semi-finished products from the Fos ingot casting, in order to allow this plant to enter new bearings markets.

At the outset, the undertakings made by the two parties in terms of the quantities of steel produced are as follows: 175,000 tons per year for Ascometal, and 100,000 tons per year for Vallourec. These volumes would secure the steel mill's long-term operations and competitiveness.

Management and employee representatives were informed today about this stage of the process of the partial sale of the steel mill.

About Vallourec Vallourec is a world leader in premium tubular solutions for the energy markets and for demanding industrial applications such as oil & gas wells in harsh environments, new generation power plants, challenging architectural projects, and high-performance mechanical equipment. Vallourec's pioneering spirit and cutting-edge R&D open new technological frontiers. Operating in more than 20 countries, its 20,000 dedicated and passionate people work hand-in-hand with their customers to offer more than just tubes: they deliver innovative, safe, competitive and smart tubular solutions, to make every project possible.

Listed on Euronext in Paris (ISIN code: FR0000120354, Ticker VK) and eligible for the Deferred Settlement System (SRD), Vallourec is included in the following indices: SBF 120 and Next 150.

In the United States, Vallourec has established a sponsored Level 1 American Depositary Receipt (ADR) program (ISIN code: US92023R2094, Ticker: VLOWY). Parity between ADR and a Vallourec ordinary share has been set at 5:1.

About Ascometal

ASCOMETAL is a European leader in Specialty Long steel products dedicated to the Automotive, Bearings, Energy and Mechanical Engineering sectors with a yearly turnover of € 500 million.  With 1550 employees, ASCOMETAL operates 5 industrial facilities located in France : 3 steel making plants (Dunkerque, Hagondange, Fos-sur-Mer) and 2 finishing centers (Custines, Saint-Etienne).  In addition, Ascometal has an industrial Joint-Venture in China (MASCOMETAL Ltd) and commercial subsidiaries in Germany, Italy, Spain, Poland and USA.  ASCOMETAL has the largest European R&D center (CREAS) located in Hagondange, focusing on specialty long steel products, with 40 employees. Innovation, know-how and quality benefiting customers are the trademark of ASCOMETAL products.

Contacts

Vallourec  Press -  Laurence Pernot - laurence.pernot@vallourec.com - Tel: +33 6 82 59 06 02 ; Heloise Rothenbuhler - Heloise.rothenbuhler@vallourec.com - Tel: +33 6 45 45 19 67                  Investor Relations - Etienne Bertrand - etienne.bertrand@vallourec.com - Tel :+33 1 49 09 35 58; Christophe Le Mignan - christophe.le mignan@vallourec.com - Tel : +33 1 40 09 38 96

Ascométal -  Maxime Lazard -  maxime.lazard@ascometal.com - Tel : +33 1.42.38.74.35

PDF version http://hugin.info/143606/R/2029857/754907.pdf

HUG#2029857

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 123

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 52

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 422

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 175

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 104

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 0

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 432

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 287

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading

Top 5 Most Recently Viewed Articles

NKGen Biotech to Present Innovative Research at Global Congress

Updated Category News Views 157

NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...

Continue Reading
Celebrating Case Managers: A Call to Action for 2025

Updated Category News Views 522

Recognizing the Contribution of Case Managers in 2025 Case managers have proven time and again to be essential contributors to the health and human services spectrum. In 2025, the two prominent organizations in the case management field—the American Case Management Association (ACMA) and the Commission for Case Manager Certification (CCMC)—have once again partnered to...

Continue Reading
Faruqi & Faruqi Investigates Ford Investor Claims

Updated Category News Views 92

Back in 2024, Faruqi & Faruqi took aim at Ford Motor Company (NYSE: F), investigating claims from investors who’d racked up losses over $100,000. They were diving deep into the financial mess at Ford—a colossal vehicle manufacturer that found itself knee-deep in allegations of breaching federal securities laws. The chatter was all about how quality assurance failures...

Continue Reading
Entourage Health Announces Going-Private Arrangement Plan

Updated Category News Views 236

Entourage Health Corp. Takes a Bold Step Toward Going-Private Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) has officially entered into a significant arrangement agreement with 1001007762 Ontario Inc. and 2437653 Ontario Inc. This strategic move, a statutory plan under the Business Corporations Act (Ontario), sees the Purchaser agreeing to acquire all common shares...

Continue Reading
A&W Revenue Royalties Income Fund Q3 2024 Results Review

Updated Category News Views 183

A&W Revenue Royalties Income Fund Q3 2024 Financial Overview TRADING SYMBOL: TSX: AW.UN A&W Revenue Royalties Income Fund has reported encouraging results for the third quarter ending this year. The quarterly performance reflects steady royalty income growth and strategic developments that promise an exciting future. Royalty Income Performance In the third quarter of...

Continue Reading